Prevention of complications after surgery for benign prostatic hyperplasia

Authors

  • Ю. М. Гурженко ДУ «Інститут урології НАМН України»
  • В. В. Спиридоненко ДУ «Інститут урології НАМН України»
  • Ф. З. Гайсенюк Національна медична академія післядипломної освіти імені П.Л. Шупика, м. Київ

DOI:

https://doi.org/10.30841/2307-5090.2(57).2016.82974

Keywords:

TURP, benign prostatic hyperplasia, Prostamol Uno, Flosin, lower urinary tract symptoms

Abstract

The aim of the study: to evaluate the clinical efficacy of monotherapy with drugs of herbal medicine and -adrenergic receptors and their combinations in patients with benign prostatic hyperplasia (BPH) stage II-III after transurethral resection of the prostate (TURP). Materials and methods. All patients (n=145) were divided into four clinical groups depending on methods of therapy. Patients of the 1st group (n=42) were not prescribed medications after the TURP for them was established active surveillance. Patients of the 2nd group (n=38) received monotherapy with the drug Prostamol Uno. Patients of the 3rd group (n=31) received the drug Flosin. Patients of the 4th group (n=34) received combination therapy drugs Prostamol Uno and Flosin. Results. There were defined the criteria of the effectiveness of medical therapy after surgical treatment of BPH: increased RV by 25%, increased volume by 50%, reducing the average speed of urination, frequency of nighttime urination, IPSS and QoL data. During the year after the TURP the condition of the patients improved markedly, but significant difference in the performance of active surveillance and the groups receiving monotherapy and combined treatment. Conclusion. The early postoperative period after TURP is an indication for long-term combination therapy with drugs Prostamol Uno and Flosin, which is pathogenetically a highly effective and safe, contributes to the rapid elimination of irritative and obstructive symptoms improved quality of life of the patient.

Author Biographies

В. В. Спиридоненко, ДУ «Інститут урології НАМН України»

Спиридоненко Владимир Владимирович

Ф. З. Гайсенюк, Національна медична академія післядипломної освіти імені П.Л. Шупика, м. Київ

Гайсенюк Федор Зиновьевич

ГУ «Институт урологии НАМН Украины»

References

Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany // Eur. Urology. – 2001. – V. 39. – P. 682.

Pereverzev A.S., Sergienko N.F. Adenoma predstatel'noj zhelezy. – K., 1998. – 278 s.

De Marzo A.M. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.

Savust'janenko A.V. Fokusuvannja na medikamentoznomu likuvanni dobrojakisnoi' giperplazii' (za materialami 15-i' Central'nojevropejs'koi' konferencii' Jevropejs'koi' asociacii' urologiv: SEM 15) // NMiF № 13 (548). – 2015. – S. 3–4.

Aliaev I.G, Vinarov A.Z, Demidko I.L, Spivak L.G. The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia //Urologiia. – 2013. – Jul-Aug; (4). – R. 32–6.

Issue

Section

Urology